Cummings, Jeffrey L. http://orcid.org/0000-0001-8944-4158
Osse, Amanda M. Leisgang
Kinney, Jefferson W.
Funding for this research was provided by:
National Institute of General Medical Sciences (P20GM109025)
National Institute of Neurological Disorders and Stroke (U01NS093334)
National Institute on Aging (R01AG053798, P20AG068053, P30AG072959, R35AG71476)
Alzheimer's Drug Discovery Foundation
Ted and Maria Quirk Endowment
Joy Chambers-Grundy Endowment
Article History
Accepted: 28 August 2023
First Online: 20 September 2023
Declarations
:
: None.
: JC has provided consultation to Acadia, Actinogen, Acumen, AlphaCognition, Aprinoia, AriBio, Artery, Biogen, BioVie, Cassava, Cerecin, Diadem, EIP Pharma, Eisai, GemVax, Genentech, GAP Innovations, Janssen, Jocasta, Karuna, Lilly, Lundbeck, LSP, Merck, NervGen, Novo Nordisk, Oligomerix, Optoceutics, Ono, Otsuka, PRODEO, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, Suven, SynapseBio, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies. AL and JK have no disclosures.
: Not applicable, no human subjects included.
: Not applicable, no human subjects included.
: Available on public website clinicaltrials.gov.
: Not applicable, no special programing was employed.
: All authors have taken part in the outline, revision of multiple drafts, and review and approval of the final version of the manuscript.
: Not applicable.